JP2019520550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520550A5 JP2019520550A5 JP2018555652A JP2018555652A JP2019520550A5 JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5 JP 2018555652 A JP2018555652 A JP 2018555652A JP 2018555652 A JP2018555652 A JP 2018555652A JP 2019520550 A5 JP2019520550 A5 JP 2019520550A5
- Authority
- JP
- Japan
- Prior art keywords
- dpp3
- pharmaceutical composition
- inhibitor
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102100020750 Dipeptidyl peptidase 3 Human genes 0.000 claims 9
- 101000931862 Homo sapiens Dipeptidyl peptidase 3 Proteins 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000001338 necrotic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000002617 apheresis Methods 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 claims 1
- 210000001218 blood-brain barrier Anatomy 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110620A JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16166476.8 | 2016-04-21 | ||
| EP16166476 | 2016-04-21 | ||
| PCT/EP2017/059377 WO2017182561A1 (en) | 2016-04-21 | 2017-04-20 | Methods for determining dpp3 and therapeutic methods |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Division JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Division JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019520550A JP2019520550A (ja) | 2019-07-18 |
| JP2019520550A5 true JP2019520550A5 (enExample) | 2020-05-28 |
Family
ID=56014788
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555652A Pending JP2019520550A (ja) | 2016-04-21 | 2017-04-20 | Ｄｐｐ３の定量方法および治療方法 |
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A Pending JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076521A Active JP7219737B2 (ja) | 2016-04-21 | 2020-04-23 | Ｄｐｐ３の定量方法および治療方法 |
| JP2022110620A Pending JP2022163014A (ja) | 2016-04-21 | 2022-07-08 | Ｄｐｐ３の定量方法および治療方法 |
| JP2024178873A Pending JP2025011237A (ja) | 2016-04-21 | 2024-10-11 | Ｄｐｐ３の定量方法および治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190145981A1 (enExample) |
| EP (5) | EP3446125B1 (enExample) |
| JP (4) | JP2019520550A (enExample) |
| KR (3) | KR102886883B1 (enExample) |
| CN (3) | CN120093910A (enExample) |
| AU (2) | AU2017252212B2 (enExample) |
| BR (1) | BR112018071583A2 (enExample) |
| CA (1) | CA3021252A1 (enExample) |
| CH (1) | CH713803B1 (enExample) |
| DE (1) | DE112017002105T5 (enExample) |
| IL (1) | IL262472B2 (enExample) |
| MX (3) | MX2018012856A (enExample) |
| MY (1) | MY200300A (enExample) |
| SG (1) | SG11201809252YA (enExample) |
| WO (1) | WO2017182561A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3446125B1 (en) * | 2016-04-21 | 2024-08-28 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and diagnostic methods |
| MY202502A (en) * | 2017-10-25 | 2024-05-01 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress |
| US20220211798A1 (en) * | 2018-12-21 | 2022-07-07 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| MX2022002432A (es) * | 2019-08-30 | 2022-06-02 | 4TEEN4 Pharmaceuticals GmbH | Orientacion terapeutica y/o monitoreo terapeutico para el tratamiento de choques. |
| US20230104578A1 (en) * | 2020-02-27 | 2023-04-06 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| CA3172349A1 (en) * | 2020-02-27 | 2021-09-02 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
| US20230250166A1 (en) | 2020-02-27 | 2023-08-10 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
| EP3922993A1 (en) * | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| MX2022011583A (es) * | 2020-03-16 | 2022-10-18 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 en pacientes infectados con coronavirus. |
| IL315632A (en) | 2022-03-15 | 2024-11-01 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| CN117186177B (zh) * | 2022-05-31 | 2024-08-23 | 中国农业大学 | 一种具有降尿酸活性的鸭血球蛋白肽及其制备方法 |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| JP2025527173A (ja) | 2022-07-29 | 2025-08-20 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 敗血性ショックを有する患者におけるｄｐｐ３の増加の予測 |
| JP2025541138A (ja) | 2022-12-15 | 2025-12-18 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤 |
| CN115804836A (zh) * | 2022-12-27 | 2023-03-17 | 中国人民解放军海军特色医学中心 | 一种中枢小分子蛋白dpp3在制备降压药物中的应用 |
| CN120857945A (zh) | 2023-03-29 | 2025-10-28 | 4Teen4制药有限公司 | 用于在血压下降的危重病患者中保护心肌和预防心肌损伤的dpp3抑制剂 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6188884A (ja) | 1984-10-04 | 1986-05-07 | Sankyo Co Ltd | エンケフアリナ−ゼｂ阻害物質およびその製法 |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル，インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
| JPH06219989A (ja) * | 1993-01-27 | 1994-08-09 | Microbial Chem Res Found | 新規生理活性物質フルオスタチンａおよびｂ、その製造法およびその用途 |
| GB9312324D0 (en) * | 1993-06-15 | 1993-07-28 | Pitman Moore Inc | Vaccine |
| US5612186A (en) | 1994-06-22 | 1997-03-18 | Food Industry Research And Development Institute | Enzyme-capture assay (ECA) for the identification of Escherichia coli in clinical samples |
| US5601986A (en) | 1994-07-14 | 1997-02-11 | Amgen Inc. | Assays and devices for the detection of extrahepatic biliary atresia |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2383907A1 (en) | 1999-09-01 | 2001-03-08 | Incyte Genomics, Inc. | Human hydrolytic enzymes |
| AU2002225954A1 (en) * | 2000-11-08 | 2002-05-21 | The University Of Georgia Research Foundation, Inc. | Dipeptidylpeptidases and methods of use |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| US7064107B2 (en) | 2002-06-07 | 2006-06-20 | Dyax Corp. | Prevention and reduction of blood loss |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2005106486A2 (en) * | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) |
| EP1767648A4 (en) * | 2004-06-01 | 2009-08-05 | Sysmex Corp | METHOD FOR MEASURING ENZYME ACTIVITY AND PILLAR FOR USE IN THE MEASUREMENT OF ENZYME ACTIVITY |
| EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
| JP2006230318A (ja) | 2005-02-25 | 2006-09-07 | Maruishi Pharmaceutical Co Ltd | 関節リウマチの診断方法 |
| CN100420947C (zh) * | 2005-05-30 | 2008-09-24 | 孙东旭 | 用单一捕获剂定量检测特异性分析物的方法及其试剂盒 |
| WO2007055979A2 (en) * | 2005-11-02 | 2007-05-18 | Meyer Pharmaceuticals Llc | Native trre: protein implicated in tnf receptor shedding for treating arthritis and inflammation |
| AU2007225054B2 (en) * | 2006-03-13 | 2012-08-16 | Becton, Dickinson And Company | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
| US20080057590A1 (en) | 2006-06-07 | 2008-03-06 | Mickey Urdea | Markers associated with arteriovascular events and methods of use thereof |
| DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
| CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| US8715928B2 (en) * | 2009-02-13 | 2014-05-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Molecular-based method of cancer diagnosis and prognosis |
| WO2011023685A1 (en) | 2009-08-27 | 2011-03-03 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
| CN102753569A (zh) | 2009-12-14 | 2012-10-24 | 塞尔蛋白质股份有限公司 | 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白 |
| KR101234352B1 (ko) * | 2010-03-18 | 2013-02-15 | 권동락 | 선택적 면역 세포 분리 반출장치 |
| CN103038249B (zh) | 2010-06-08 | 2016-04-13 | 皮里斯股份公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
| EP3446125B1 (en) * | 2016-04-21 | 2024-08-28 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and diagnostic methods |
-
2017
- 2017-04-20 EP EP17720047.4A patent/EP3446125B1/en active Active
- 2017-04-20 BR BR112018071583-2A patent/BR112018071583A2/pt unknown
- 2017-04-20 CN CN202510254123.6A patent/CN120093910A/zh active Pending
- 2017-04-20 DE DE112017002105.7T patent/DE112017002105T5/de active Pending
- 2017-04-20 SG SG11201809252YA patent/SG11201809252YA/en unknown
- 2017-04-20 EP EP21153560.4A patent/EP3896450A1/en active Pending
- 2017-04-20 KR KR1020237026743A patent/KR102886883B1/ko active Active
- 2017-04-20 KR KR1020247025458A patent/KR102886863B1/ko active Active
- 2017-04-20 JP JP2018555652A patent/JP2019520550A/ja active Pending
- 2017-04-20 CN CN202511191873.XA patent/CN120992960A/zh active Pending
- 2017-04-20 EP EP24178565.8A patent/EP4417217A3/en active Pending
- 2017-04-20 MY MYPI2018703855A patent/MY200300A/en unknown
- 2017-04-20 MX MX2018012856A patent/MX2018012856A/es unknown
- 2017-04-20 AU AU2017252212A patent/AU2017252212B2/en active Active
- 2017-04-20 EP EP21153574.5A patent/EP3854817A1/en active Pending
- 2017-04-20 EP EP24178574.0A patent/EP4417218A3/en active Pending
- 2017-04-20 CN CN201780039077.1A patent/CN110168372A/zh active Pending
- 2017-04-20 CH CH001280/2018A patent/CH713803B1/de unknown
- 2017-04-20 CA CA3021252A patent/CA3021252A1/en active Pending
- 2017-04-20 WO PCT/EP2017/059377 patent/WO2017182561A1/en not_active Ceased
- 2017-04-20 US US16/095,563 patent/US20190145981A1/en active Pending
- 2017-04-20 IL IL262472A patent/IL262472B2/en unknown
- 2017-04-20 KR KR1020187033194A patent/KR102565453B1/ko active Active
-
2018
- 2018-10-19 MX MX2025006655A patent/MX2025006655A/es unknown
- 2018-10-19 MX MX2020001193A patent/MX2020001193A/es unknown
-
2020
- 2020-04-23 JP JP2020076521A patent/JP7219737B2/ja active Active
- 2020-07-02 US US16/919,449 patent/US11726094B2/en active Active
-
2022
- 2022-07-08 JP JP2022110620A patent/JP2022163014A/ja active Pending
-
2023
- 2023-06-21 US US18/338,805 patent/US20240385197A1/en active Pending
- 2023-11-02 AU AU2023258417A patent/AU2023258417A1/en active Pending
-
2024
- 2024-10-11 JP JP2024178873A patent/JP2025011237A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520550A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| JP2008523083A5 (enExample) | ||
| Eppensteiner et al. | Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults | |
| Su et al. | HMGB1 blockade attenuates experimental autoimmune myocarditis and suppresses Th17‐cell expansion | |
| Chatterjee et al. | SDF‐1α induces differential trafficking of CXCR4‐CXCR7 involving cyclophilin A, CXCR7 ubiquitination and promotes platelet survival | |
| Anliker-Ort et al. | Treatment of rare inflammatory kidney diseases: drugs targeting the terminal complement pathway | |
| JP2014518883A5 (enExample) | ||
| JP2016183160A5 (enExample) | ||
| Steckelings et al. | Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists | |
| JP2011503012A5 (enExample) | ||
| IL262472B1 (en) | Dpp3 inhibitors for use in treating diseases related to necrosis | |
| JP2017500018A5 (enExample) | ||
| JP2019506159A5 (enExample) | ||
| JP2011184466A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2016529229A5 (enExample) | ||
| JP2016539121A5 (enExample) | ||
| Colafrancesco et al. | Targeting the immune system for pulmonary inflammation and cardiovascular complications in COVID-19 patients | |
| FI3553084T3 (fi) | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa | |
| CN111542546A (zh) | 抗lag-3 抗体及其用途 | |
| Zeerleder et al. | Nucleosome‐releasing factor: a new role for factor VII‐activating protease (FSAP) | |
| CN115666649A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| WO2011049412A3 (en) | Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells | |
| JP2019522974A (ja) | 抗Ｍａｃ−１抗体 |